EZH2 inhibition has ability to induce a shift of H3K27 from trimethylation to acetylation, and EZH2 inhibitor (GSK‐126) showed to markedly reduce invasiveness and significantly suppress the tumor growth in NRASmut melanoma when combined with trametinib [307, 311]. This evidence concerns the gene EZH2 and neoplasm.